Merck today announced a € 70 million expansion of its ADC manufacturing capabilities and capacity in St. Louis, Missouri, USA.
Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Expansion to create 170 jobs at Bioconjugation Center of Excellence in St. Louis, Missouri, USA